U.K trade group rebukes pharma company for 'extremely concerning' violation; evaluating the risks of an Alzheimer's drug

Taking stock of the drug industry, from the lab to the medicine chest

June 16, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Trade group scolds drugmaker for 'unethical' attempt to gain info about rival product Leo Pharma was cited for committing a "serious and extremely concerning" violation of voluntary industry codes. By Ed Silverman Opinion: The FDA needs a risk evaluation and mitigation strategy for Alzheimer's drug lecanemab As an Alzheimer's expert, I'm both optimistic and worried about lecanemab and donanemab. The health care system isn't ready. By Jason Karlawish STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Ted Jackson/AP FDA advisers endorse updating Covid vaccines to target latest Omicron strain The FDA's scientific advisers said the next round of shots in the U.S. should only include protection against the most dominant variants. By Associated Press

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser